Germany’s Stada Arzneimittel AG said Monday it would support a joint takeover offer by private-equity firms Bain Capital LLC and Cinven Group Ltd. that values the drugmaker at more than $4 billion.
Bain and Cinven are offering 66 euros ($69.90) a share for Stada as well as a dividend of EUR0.72, Stada said. The bid is markedly higher than Cinven’s earlier proposal to pay EUR56 a share.
Stada received two takeover offer after a structured bidding process. The company said its executive and supervisory board decided it was in the best interest of the company to support the offer by Bain and Cinven.
“Bain Capital and Cinven have presented the most financially appealing offer,” said Stada.
The pharmaceutical company said it had signed an investor agreement with Bain and Cinven that has “extensive protection provisions” for employees, production sites and the corporate strategy. Stada’s executive and supervisory boards will review the offer document upon its release, the company said.
“From today’s vantage point, both boards expect to be able to recommend the offer for acceptance to the shareholders,” said Stada.
By Friedrich Geiger
Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.
Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.
The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world.